

23. A vaccine composition according to claim 21 wherein the adjuvant is a preferential stimulator of TH1-cell response.
24. A vaccine composition according to claim 19 which additionally comprises a carrier.
25. A vaccine composition according to claim 23 in which the preferential stimulator of TH1-cell response is selected from the group of adjuvants comprising: 3D-MPL, 3D-MPL wherein the size of the particles of 3D-MPL is preferably about or less than 100nm, QS21, a mixture of QS21 and cholesterol, or a combination of two or more of said adjuvants.
26. A vaccine composition according to claim 25 in which the preferential stimulator of TH1-cell response is 3D-MPL.
27. A vaccine composition according to claim 20 in which the Hepatitis A antigen is derived from the HM-175 strain.
28. A vaccine composition according to claims 19, 21, 22, or 24 in which a hepatitis B antigen is additionally present.
29. A vaccine composition according to claim 28 which additionally comprises a dengue antigen.
30. A vaccine according to claim 29 in which the dengue antigen is selected from the group comprising envelope (E) glycoprotein proteins, truncated envelope glycoprotein proteins and Dengue viral proteins.
31. A vaccine composition according to claim 28 which additionally comprises a hepatitis E antigen.
32. A vaccine composition according to claim 29 which additionally comprises a hepatitis E antigen.

33. A vaccine composition as defined in claim 28 in which the Hepatitis B antigen is hepatitis surface antigen.

34. A vaccine composition according to claim 24 in which the carrier is selected from the group comprising aluminium hydroxide, aluminium phosphate and an oil in water emulsion.

35. A vaccine composition according to claim 34 in which the carrier is aluminium hydroxide.

36. A vaccine composition according to claims 19, 21, 22 or 24 which additionally comprises a dengue antigen.

37. A vaccine composition according to claim 36 in which the dengue antigen is selected from the group comprising envelope (E) glycoprotein proteins, truncated envelope glycoprotein proteins and Dengue viral proteins.

38. A vaccine composition according to claims 19, 21, 22, or 24 which additionally comprises a hepatitis E antigen.

39. A vaccine composition according to claim 38 in which the hepatitis E antigen is SAR

55.

40. A method of manufacture of Vi polysaccharide wherein the method comprises:

- (a) fermenting a preculture of *S. typhi*;
- (b) extracting and purifying the Vi polysaccharide in the absence of phenol; and
- (c) vacuum drying the Vi polysaccharide.

41. *S. typhi* Vi polysaccharide produced by the method of claim 40.